ユナイテッド・イミュニティ株式会社
Founded 2017 · 17 employees on LinkedIn · 3 known investors
Find your way into ユナイテッド・イミュニティ株式会社
United Immunity develops a myeloid-targeting platform using pullulan-based nanoparticles to selectively deliver therapeutic agents and vaccine antigens to macrophages and dendritic cells. The platform targets these immune cells through DC-SIGN receptor binding for cancer immunotherapy, vaccines, and treatment of fibrosis, viral infections, and inflammatory diseases.
Investors · 3
.png){kind=logo}
Frequently asked questions
- What does ユナイテッド・イミュニティ株式会社 do?
- United Immunity develops a myeloid-targeting platform using pullulan-based nanoparticles to selectively deliver therapeutic agents and vaccine antigens to macrophages and dendritic cells. The platform targets these immune cells through DC-SIGN receptor binding for cancer immunotherapy, vaccines, and treatment of fibrosis, viral infections, and inflammatory diseases.
- Who are ユナイテッド・イミュニティ株式会社's investors?
- ユナイテッド・イミュニティ株式会社's investors include Nippon Venture Capital, UTEC, Aozora Corporate Investment.